Nobelpharma Visited Keanrui Pharmaceutical Group Headquarters. 

    The Managing Director&CEO SHIOMURA of Nobelpharma Co., Ltd Japan.(NPC) visited the headquarters of Keanrui (Beijing) Pharmaceutical Group Co., Ltd in Beijing China on the afternoon of 8th December,,2023 . During the meeting, the two sides had friendly discussions. They communicated about the commercialization progress of the rare disease drug Xian Luoli® (Generic name: Sirolimus Gel) and had an in-depth discussion about future cooperation in other products.

Managing Director&CEO SHIOMURA and President Li Chao

    The Chinese delegation was led by Mr. Li Chao, the president of Keanrui Pharmaceutical Group, and including Mr. Sun Jie, the vice president of marketing, Mr. Cao Qizhong, the general manager of the marketing center and others. Representatives from Japan include Mr. Jin SHIOMURA, the NPC founder, Mr. Masa Onozaki, the head of NPC global business department, Mr. Jiang Rongzhe, the general manager of NPCH.

    President Li Chao expressed his sincere welcome to the Japanese guests. Mr. Masa  expressed his gratitude to the Chinese side for their hospitality.

    During the meeting, the two sides firstly introduced and discussed the commercialization progress of Xian Luoli®. NPC and NPCH expressed satisfaction with the achievements made by Keanrui so far and communicated and coordinated on the next stage plan. Managing Director & CEO SHIOMURA expressed his sincere gratitude to Keanrui for its efforts in promoting the product's entry into the national medical insurance. Subsequently, the two sides also introduced and exchanged other potential rare disease drugs of Nobelpharma, expressing their willingness to carry out cooperation in more areas and bring benefits to Chinese patients with rare diseases.

    Xian Luoli® (Generic name: Sirolimus Gel) was approved by the National Medical Products Administration on 9th June, 2023 through the priority review and approval process, for the treatment of facial angiofibromas in children and adults aged 6 years and above with tuberous sclerosis complex, it is the only drug in the world that has demonstrated efficacy in treating facial angiofibromas and head plaques in patients with tuberous sclerosis complex. As the only mTOR inhibitor that can be administered locally, the product is easy to use, non-invasive, and highly safe.

    Nobelpharma is the largest orphan drug developer in Japan, specializing in providing innovative treatment options for patients with rare diseases. The company has multiple orphan drug candidates in research or already on the market.

    Keanrui (Beijing) Pharmaceutical Group Co., Ltd was founded in 2000 and has developed into a comprehensive group company integrating new drug research and development, drug production, professional academic promotion, marketing, and drug sales and distribution. Keanrui Pharmaceutical Group adheres to the corporate mission of " Caring for the peace and tranquility of mankind and working towards the prosperity of life " and adheres to the corporate values of " Helping the world, advocating morality, thinking wisely, practicing diligently ". The company focuses on innovating in the pharmaceutical industry and developing drugs with clinical advantages, meeting unmet medical needs through the excellent marketing and sales capabilities.

Both parties took a group photo

    After the meeting, President Li Chao personally led Managing Director&CEO SHIOMURA and his delegation to visit the company's headquarters, introducing the development history of Keanrui in detail and introducing the company's series of well-known products. Mr. SHIOMURA expressed his praise for Keanrui Group's achievements. At last, both sides expressed that this meeting was an important milestone in the cooperation between the two parties and a new height in their friendship. Nobelpharma will further accelerate the registration process of new products in China, while Keanrui Pharmaceutical Group will further expand its presence in the field of rare diseases. The two sides will continue to maintain close communication and collaboration, making contributions to promote the development and popularization of rare disease drugs in China.